Impact of recurrent hospitalization for Clostridioides difficile on longitudinal outcomes in patients with inflammatory bowel diseases: a nationally representative cohort

Preethi G Venkat; Nghia H Nguyen; Jiyu Luo; Alexander S Qian; Sahil Khanna; Siddharth Singh

doi:10.1177/17562848221141501

Impact of recurrent hospitalization for Clostridioides difficile on longitudinal outcomes in patients with inflammatory bowel diseases: a nationally representative cohort

Therap Adv Gastroenterol. 2022 Dec 8:15:17562848221141501. doi: 10.1177/17562848221141501. eCollection 2022.

Authors

Preethi G Venkat¹, Nghia H Nguyen¹, Jiyu Luo², Alexander S Qian¹, Sahil Khanna³, Siddharth Singh^{4

5}

Affiliations

¹ Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
² Division of Biostatistics, Department of Public Health Education, University of California San Diego, La Jolla, CA, USA.
³ Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
⁴ Division of Gastroenterology, Department of Medicine, University of California San Diego, 9452 Medical Center Dr., ACTRI 1W501, La Jolla, CA 92093, USA.
⁵ Division of Biomedical Informatics, Department of Medicine, University of California San Diego, La Jolla, CA, USA.

Abstract

Background: Clostridioides difficile infection (CDI) is associated with poor outcomes in patients with inflammatory bowel diseases (IBD).

Objectives: We conducted a nationally representative cohort study to evaluate the impact of recurrent CDI (rCDI)-related hospitalization on longitudinal unplanned healthcare utilization in patients with IBD.

Design: This was a retrospective cohort study that utilized the 2017 Nationwide Readmissions Database (NRD).

Methods: We identified 13,446 patients with IBD, hospitalized at least twice from January to June 2017 and followed through December 2017; of these, 1,148 had CDI-related hospitalizations. We compared the annual burden of hospitalization and IBD-related surgery in IBD patients with rCDI-related admission versus single CDI-related admission (primary reference), and those with one or more CDI-related admission versus no CDI-related admission (secondary reference).

Results: There were no significant differences in risk and burden of unplanned healthcare utilization (time spent in-hospital, 27 days versus 27 days, p = 0.62), 6-month readmission (63% versus 64.3%, p = 0.8) or IBD-related surgery in patients with recurrent (two or more) CDI-related hospitalizations versus single CDI-related admission. However, patients with ⩾1 CDI-related admission versus no CDI admissions experienced higher rate of 6-month readmission (61.1% versus 55.7%, p<.001), total days spent in the hospital per year (median: 26 days versus 21 days, p<.001), total cost across all hospitalizations per year ($212,524 versus $184,384, p < 0.01), and inpatient mortality (3.28% versus 1.81%, p = 0.01), without an increase in risk of IBD-related surgery (6.7% versus 6.4%, p = 0.79).

Conclusion: While patients with IBD hospitalized for CDI have poor longitudinal inpatient outcomes, recurrent admissions for CDI may not increase risk of adverse outcomes compared to one-time admission.

Keywords: Crohn’s disease; diarrhea; hospitalization; infection.